Revolutionizing cancer diagnosis with AI

We develop efficient and reliable AI solutions for the early detection of cancers, aiming to improve patient care.

TechnologY

VisioCyt®

Developed from French research and protected by five patents, our VisioCyt® technology uses deep learning and computer vision algorithms to analyze and provide a diagnosis on digitized cytology slides.

Solutions

Our AI solutions for cancer detection

VisioCyt® Bladder

VisioCyt® Bladder is a non-invasive test for the diagnosis and follow-up of bladder cancer using a simple urine sample.

VisioCyt® Screening

Currently in development, VisioCyt® Screening is a test for bladder cancer screening in asymptomatic, high-risk patients.

VisioCyt® Thyroid

Currently in development, VisioCyt® Thyroid is a test for the diagnosis of thyroid cancer using a fine-needle thyroid biopsy.

NEWS

All our news

Stay informed about the latest news and events from VitaDX.

News

Date: 2 April 2026

VisioCyt® Bladder obtains temporary coverage under the RIHN 2.0 program: a major breakthrough for the non-invasive diagnosis of bladder cancer

VisioCyt® Bladder, an innovative non-invasive solution for diagnosing bladder cancer, is now covered under the national RIHN 2.0 program following a favorable joint evaluation by...

News

Date: 6 June 2025

The French National Authority for Health (HAS) issues a favorable opinion on the exceptional reimbursement coverage of VisioCyt® Bladder.

VitaDX welcomes the favorable opinion issued by the French National Authority for Health (HAS) on June 5, 2025, regarding the exceptional reimbursement coverage of digitized...

Learn more

Would you like to learn more about our solutions, our technology, or our partnerships?

Whether you are a healthcare professional, an investor, or an end user, our team is available to inform and guide you.